key: cord-0773325-m6kr5ej6
authors: Rebić, Nevena; Park, Jamie; Garg, Ria; Ellis, Ursula; Kelly, Ayano; Davidson, Eileen; De Vera, Mary A.
title: A rapid review of medication taking (‘adherence’) among patients with rheumatic diseases during the COVID‐19 pandemic
date: 2021-07-05
journal: Arthritis Care Res (Hoboken)
DOI: 10.1002/acr.24744
sha: 35d94aec08d8587f412b0371af70d17f352d991c
doc_id: 773325
cord_uid: m6kr5ej6

OBJECTIVES: We aimed to identify, appraise, synthesize, and contextualize rapidly emerging reports on medication taking (‘adherence’) among patients with rheumatic diseases during the COVID‐19 pandemic. METHODS: We searched MEDLINE, EMBASE, and CINAHL for peer‐reviewed communications, letters, and manuscripts published during the COVID‐19 pandemic evaluating medication taking among individuals with rheumatic diseases. We appraised assessment and reporting of medication adherence according to established definitions of three distinct problems of medication taking (i.e., non‐initiation, poor implementation, and discontinuation) and pooled findings using random effects models. RESULTS: We included 31 peer‐reviewed studies in our synthesis from various jurisdictions, of which 25 described medication taking among rheumatology patients and 6 described medication prescribing among rheumatology providers. The pooled prevalence of overall medication non‐adherence was 14.8% (confidence interval [CI]: 12.3%, 17.2%) and that of medication discontinuation (i.e., stopping of prescriptions) and poor implementation (i.e., not taking medication at the dose/frequency prescribed) as 9.5% (CI: 5.1%, 14.0%) and 9.6% (CI: 6.2%, 13.0%), respectively. Non‐initiation (i.e., not starting/not filling new prescriptions) was not addressed. CONCLUSIONS: Medication taking among individuals with rheumatic diseases during the COVID‐19 pandemic varies globally. Unclear reporting and extensive variation in research methods between studies creates barriers to research replication, comparison, and generalization to specific patient populations. Future research in this area should use consistent and transparent approaches to defining and measuring medication taking problems in order to ensure findings appropriately describe the epidemiology of medication adherence and have the potential to identify modifiable targets for improving patient care.

In response to the COVID-19 pandemic, international recommendations for rheumatic disease management were rapidly released including those from the Canadian Rheumatology Association (CRA) 1 , the American College of Rheumatology (ACR) 2 , and the European League Against Arthritis and Rheumatism (EULAR) 3 , all of which consistently call for adherence to medication therapies, including conventional synthetic, biologic, and targeted synthetic disease modifying antirheumatic drugs (csDMARDs, bDMARDs, tsDMARDs) as well as other therapies such as NSAIDs [1] [2] [3] . Indeed, taking medications as prescribed is important to the management of rheumatic diseases across both routine and exceptional circumstances, such as the COVID-19 pandemic, as patients rely on medications to relieve symptoms, perform daily life activities, and prevent irreversible joint and organ damage. However, as a result of the COVID-19 pandemic, adherence with therapies among patients with rheumatic diseases has become increasingly complex due to healthcare system factors, such as the occurrence of medications shortages and limitations on nonessential healthcare visits. For example, hydroxychloroquine (HCQ), a csDMARD used to treat systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), was initially speculated to be a viable treatment for COVID-19, leading to concerns regarding access for patients with rheumatic diseases. Early reports of successful treatment with HCQ 4 and emergency authorization by the US Food and Drug Administration led to critical shortages in medication availability 5 . The therapeutic efficacy of interleukin-6 (IL-6) inhibitor against COVID-19 has also been discussed in a recent systematic review and meta-analysis 6 . Condition-and patient-related factors may also place barriers to optimal rheumatic disease management and patients' medication taking as prescribed. Indeed, patients with rheumatic disease are known to be at higher risk of infection secondary to immune-modulating treatments, immune-dysfunction, and presence of comorbidities 7 . As such, concerns regarding immunosuppressive effects secondary to antirheumatic therapy may contribute to non-adherence to medications.

Since the start of the COVID-19 pandemic, numerous reports have assessed experiences with medication taking among patients with rheumatic diseases. Accordingly, we conducted a rapid review to systematically identify studies, synthesize findings, and describe the data to date examining the medication taking experiences among this patient population as well as the prescribing experiences of rheumatology providers.

This article is protected by copyright. All rights reserved

We conducted a rapid review informed by guidelines from the Cochrane Rapid Reviews Methods Group 8 . A search strategy was developed collaboratively with all authors, including an information scientist (UE), to identify peer-reviewed studies on medication taking ('adherence') among patients with rheumatic diseases during the COVID-19 pandemic. Searches were performed by UE of the databases, Ovid MEDLINE (from March 2020), Ovid EMBASE (from March 2020), and CINAHL (from March 2020), using subject headings and keywords of unindexed terms related to "medication adherence", "rheumatic diseases" and "COVID-19". Additional resources were searched, including the Cochrane COVID-19 Study Register, Epistemonikos COVID-19 Living Overview of Evidence, and Prospero. The searches were conducted on January 13, 2021 (see Appendix 1 in Supplementary Materials for the complete search strategy).

Two authors (NR, RG) screened titles and abstracts for peer-reviewed concise communications, letters, and manuscripts that fulfilled inclusion criteria of: 1) observational design; 2) study sample including individuals with rheumatic disease (e.g., ankylosing spondylitis, psoriatic arthritis, RA, SLE) and/or health care providers; 3) evaluation of medication taking ('adherence') among individuals with rheumatic disease; and 4) during the COVID-19 pandemic. Any conflicts were resolved via consensus and/or consultation with the corresponding author (MDV). The Covidence platform was used to support the screening process.

Two study authors (NR, JP) extracted information on type of publication (e.g., full manuscript, letter), country, study period, and study sample characteristics including information on type(s) of rheumatic disease, age, and sex. In extracting information on medication taking problems among rheumatology patients, we applied definitions by the International Society of Medication Adherence 9 that describe distinct problems of medication-taking corresponding to three types of medication non-adherence: 1) non-initiation, that is, not filling a prescription or starting a dosing regimen; 2) poor implementation of the dosing regimen, where scheduled doses are delayed or omitted; and 3) discontinuation or stopping of Accepted Article drug therapy. Instances when authors reported a cumulative measure not defined as any of the aforementioned types of medication-taking problems were assigned as overall medication non-adherence.

In addition to extracting and classifying medication taking according to each type of medication nonadherence, we also extracted corresponding information on the extent of the problem (e.g., % of patients), as well as potential reasons, when available. If a newer publication for the same study previously identified was found, only the newer results were extracted, unless the earlier publication reported information that was not reported in the more recent publication. With respect to papers describing prescribing by rheumatology providers, we extracted information on reported practice patterns (e.g., continuing, switching, delaying, discontinuing medications) and experiences (e.g., drug shortages) during the COVID-19 pandemic.

We appraised the quality of medication adherence measurement and reporting using the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Medication Compliance and Persistence Special Interest Group 10 as we have done in prior systematic reviews on medication adherence in rheumatic diseases 11,12 . We adapted and condensed this checklist, which aims to establish standards for reporting of medication adherence studies, to ten priority items (e.g., clarity of study objectives, description of data collection methods/data source, explicit definition of medication taking problem), awarding a single point for each criterion for a maximum score of ten.

We conducted a narrative synthesis of included studies. Where possible, we also pooled reported prevalence of medication non-adherence according to each type of medication taking problem -noninitiation, poor implementation, discontinuation -as well as overall non-adherence using random-effects models. We used the proportion (of patients) and corresponding 95% CIs as estimates. All data analysis was performed using Stata V. 15 (StataCorp, College Station, TX, USA).

Our search identified 273 articles after the exclusion of duplicates (Figure 1 ). Of these, we identified 35 studies that met our inclusion criteria, including 25 assessing medication taking among rheumatology patients and 6 assessing medication prescribing among rheumatology providers.

This article is protected by copyright. All rights reserved

We described the characteristics of 25 included studies assessing medication taking in Table 1 .

Altogether, studies spanned several countries predominantly located across the Asian, European, north African, and North American continents. All of the studies were based on self-report, with the majority based on surveys and 4 based on interviews.

The quality appraisal score of included studies is reported in Appendix 2 of Supplementary Materials. The majority of studies clearly described their aims, their study sample, the timeframe for data collection, and methods for determining medication taking problem(s). All studies described their methods for data collection and appropriately presented findings on medication taking; however, the majority of studies did not define medication taking problem(s) ('non-adherence') and none used accepted definitions. Overall, definitions of medication non-adherence varied between reports making it challenging to meaningfully synthesize findings.

Twelve studies (n=22,842) reported the overall prevalence of non-adherence to therapy, which ranged from 6.5% to 34.2% of patients. Pooling the crude estimates of overall non-adherence resulted in a prevalence of 14.8% (CI: 12.3%, 17.2%) (see Figure 2 .a.). No studies reported on non-initiation (i.e., not starting/not filling new prescriptions). Six studies (n= 3,884) reported the overall prevalence of poor implementation (i.e., not taking medication at the dose/frequency prescribed), which ranged from 2.7% to 16.4%. Pooling the crude estimates of poor implementation resulted in a prevalence of 9.5% (confidence interval [CI]: 5.1%, 14.0%)(see Figure 2 .b.). Ten studies (n=7087) reported the overall prevalence of medication discontinuation (i.e., stopping prescription), which ranged from 2% to 31.4%.

Pooling the crude estimates of discontinuation resulted in a prevalence of 9.6% (CI: 6.2%, 13.0%)(see Figure 2 .c.). Six studies 13-18 additionally reported on specific counts based on medication type (i.e., csDMARDs, bDMARDs, tsDMARDs, corticosteroids, NSAIDs, etc) with one reporting on HCQ specifically 18 . Three of these studies 13,15,17 provided specific counts for the type of medication change (i.e., dose increase/decrease, frequency changes). Two studies 16, 19 collected repeated measures of medication taking (i.e., >1 timepoints) within their sample.

The majority of studies reported some findings related to reasons for medication taking changes.

Glintbourg et al. 16 

This article is protected by copyright. All rights reserved working (OR 1.52, CI: 1.16 to 1.99, p=0.003), and use of bDMARDs (OR 1.86, CI: 1.02 to 3.81 , p=0.05) were associated with patients changing at least one medication due to fear of COVID-19. Fragoulis et al. 20 performed univariable logistical regression analyses and found that therapy discontinuation due to fear of immunosuppression was associated with unemployment (OR 9.19, 1.30 to 64.7, p=0.03) and COPD (OR 27.53, 3.17 to 239.1, p=0.003). George et al. 21 preformed univariable logistical regression analyses and found that participants who stopped a DMARD were more likely to avoid office visits (OR 1.46, 95% CI:

1.04 to 2.04, p=0.03) and to report that telehealth options were not available to them (OR 2.26, 95% CI:

1.25 to 4.08, p<0.01). Additionally, some studies examined issues related to medication taking, which included lack of medication availability 16,20,22- 18, 32, 33 noted whether medication changes were patient or prescriber initiated. However, most studies did not adequately describe how identified medication taking issues related to the specific types of non-adherence and therefore these results were challenging to synthesize.

We described the characteristics of 6 included studies assessing medication prescribing in Table 2 . Most studies 35-39 reported on medication shortages, specifically HCQ and tocilizumab which ranged from 38.9% 36 to 71% 38 and 8.9% 36 to 14% 37 , respectively. Several studies 35-37 reported on providers avoiding starting or switching to a new DMARD during the COVID-19 pandemic, ranging from 20% 36 to 74% 37 .

Two of these studies specifically reported on providers reluctance to start or switch to a bDMARD or tsDMARD, which ranged from 57.6% 35 to 74% 37 , and some reasons for this, included patient's fear to start these medications and decreased patient access to rheumatology care (e.g., screening procedures) 35 .

Overall, four studies 35-37,40 that provided specific counts for the type of medication change based on medication type. Of these, three 35,36,40 reported on bDMARD medication prescribing with 50% 40 to 84.2% 36 remaining unchanged. Additionally, three studies 35,37,40 reported providers reducing the dose/frequency of steroids, ranging from 23% 37 to 56% 40 , and three studies 36,37,40 reported providers Accepted Article reducing the dose/frequency of NSAIDs, ranging from 11% 40 to 15% 37 . Overall, measures of prescribing practices varied between reports making it challenging to compare findings.

There has been a rapid emergence of peer-reviewed reports describing medication taking among patients with rheumatic diseases during the COVID-19 pandemic, highlighting the importance of medication adherence in rheumatology care. Systematically identifying and synthesizing these reports, our rapid review identified 31 studies of medication taking during the COVID-19 pandemic, including 25 from the perspective of patients with rheumatic disease and 6 from the perspective of healthcare providers prescribing medication for rheumatic disease treatment. Altogether, with pooled prevalence of 9.5% for poor implementation, 9.6% for discontinuation, and 14.8% for medication non-adherence overall, suggesting that most patients with rheumatic disease are taking medications as prescribed during the COVID-19 pandemic. Nevertheless our narrative synthesis identified a number of serious barriers to accessing medications and care from both patient and providers perspectives.

Synthesizing findings across studies to generate pooled estimates on the prevalence of medication non-adherence provides an indicator of the extent of potential medication taking problems and can help to identify target areas for intervention with respect to different types of medication taking problems.

Only three studies 16, 20, 21 in our review conducted regression analyses to identify factors associated with medication non-adherence with only one examining multivariable analyses that reported that patients who changed the dose of at least one of their medications due to fear of COVID-19 were more frequently male, treated with bDMARDs, ≤39 years of age (compared to ≥80 years), higher educated, and working.

Also important is identifying reasons for non-adherence, including systemic (e.g., medication shortages, challenges obtaining medications) as well as individual barriers (e.g., personal beliefs, fears, or capacity to prioritize medication taking) to accessing medications and medical care identified in our review.

Moreover, characterizing the impact of the COVID-19 pandemic on how rheumatology providers approach medication prescribing is essential to understanding the context for changes in medication taking among patients, including whether they are patient or provider initiated.

In order to ensure emerging research findings can both be replicated and compared across studies, it is critical that researchers use consistent and transparent approaches to defining and measuring medication taking problems. Specifically, we recommend that researchers distinguish between the specific

This article is protected by copyright. All rights reserved types of medication taking problems 41 (i.e., non-initiation, poor implementation, and discontinuation) in order to ensure that reporting on this topic appropriately describes the extent of this issue and identifies modifiable targets and areas of intervention that may better support patient care. Moreover, systematically reporting specific counts based on medication type and medication taking change (i.e., dose increase/decrease, frequency changes) as well as collecting repeated measures of medication taking (i.e., >1 timepoints) within their sample can help provide a more thorough understanding of the phenomenon and add rigor to study findings.

Strengths and limitations of our study warrant discussion. To ensure a thorough literature search, we developed our search strategy in collaboration with an information scientist who executed all database searches. We also took a structured approach to data extraction, particularly, in using definitions by the International Society of Medication Adherence 9 as a framework to identify and describe three distinct problems of medication-taking corresponding to three types of medication non-adherence, that is noninitiation, poor implementation, and early discontinuation. Nonetheless, our systematic review may be vulnerable to publication bias given this limitation is inherent to systematic reviews. With the exception of one study that was translated from German 44 , our included studies were published in English and relevant publications in other languages may have been missed. In addition, results of our meta-analyses suggested heterogeneity between studies, reflecting the wide variation in approaches to defining and measuring medication taking problems and we caution the interpretation of pooled estimates. Moreover, the variation in reported prevalence of non-adherence and range of issues impacting medication taking during the COVID-19 pandemic demonstrate the relevance of examining adherence by jurisdiction, given regional differences in healthcare systems and pandemic management.

Altogether, our rapid review shows that medication taking among individuals with rheumatic disease during the COVID-19 pandemic varies globally. As the COVID-19 pandemic progresses, assessing its impact on healthcare provision, particularly among vulnerable patient populations, is needed.

Moreover, it is important that researchers in this area ensure that research findings have the potential to inform patient care through standardizing methods used to assess and measure medication adherence.

Characteristics of included studies assessing medication taking among rheumatology patients. 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

CRA Updated Statement on COVID-19 -March

COVID-19 in French patients with chronic inflammatory rheumatic diseases: Clinical features, risk factors and treatment adherence

Biologics, spondylitis and COVID-19

Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey

Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry

Impact of Home Confinement During the COVID-19 Pandemic on Medication Use and Disease Activity in Spondyloarthritis Patients

COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort

Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic

Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic

Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience

Accepted Article